{"id":"NCT03156621","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-03","primaryCompletion":"2019-09-27","completion":"2020-02-13","firstPosted":"2017-05-17","resultsPosted":"2021-06-29","lastUpdate":"2021-06-29"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["PRALUENT®","REGN727","SAR236553"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Alirocumab SC Q2W","type":"EXPERIMENTAL"},{"label":"Placebo SC Q2W","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.\n\nThe secondary objectives of the study are:\n\n* To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein \\[Apo\\] A-1 and B, non-high-density lipoprotein cholesterol \\[non-HDL-C\\], total-cholesterol \\[TC\\], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides \\[TG\\]) in participants with HoFH\n* To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH\n* To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH\n* To assess the potential development of anti-drug (alirocumab) antibodies","primaryOutcome":{"measure":"Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Placebo in DBTP","deltaMin":8.6,"sd":6.3},{"arm":"Alirocumab 150 mg SC Q2W","deltaMin":-26.9,"sd":4.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["United States","Austria","Canada","Czechia","France","Germany","Greece","Italy","Japan","South Africa","Taiwan","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["32646561"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Upper respiratory tract infection"]}}